PureTech’s LYT-200 receives FDA fast track for blood cancer

🌐 Investing.com (Cyprus) —
PureTech’s LYT-200 receives FDA fast track for blood cancer

AI Summary

PureTech’s LYT-200 treatment has received FDA fast track designation for blood cancer, accelerating its clinical development. This designation highlights the drug's potential to address unmet medical needs in oncology.

Markets Deals Health AI & Tech PureTech LYT-200 FDA fast track blood cancer oncology clinical development

Read original source →